Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: CFZ533
DRUG: Placebo to CFZ533
DRUG: LYS006
DRUG: Placebo to LYS006
DRUG: MAS825
DRUG: Placebo to MAS825
DRUG: LOU064 25mg
DRUG: LOU064 100mg
DRUG: Placebo to LOU064
DRUG: VAY736
DRUG: Placebo to VAY736

Sponsor

Novartis Pharmaceuticals